BCL2 and cancer: Our data led us to infer that such aberrant SATB1 expression might endow cells with excess ability to resist apoptosis by maintaining the higher-order chromatin structure in favor of the expression of anti-apoptotic genes such as the BCL2 gene, thus suppressing pro-apoptotic genes, and consequently providing the cancer cells with selective advantages.